Lumexa Imaging (NASDAQ:LMRI) Issues FY 2026 Earnings Guidance

Lumexa Imaging (NASDAQ:LMRI) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.710-0.770 for the period, compared to the consensus estimate of 0.620. The company issued revenue guidance of $1.0 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Lumexa Imaging Price Performance

Shares of NASDAQ LMRI opened at $12.20 on Friday. The firm’s 50-day simple moving average is $10.78 and its 200 day simple moving average is $10.90. The stock has a market cap of $1.17 billion and a P/E ratio of -20.68. The company has a quick ratio of 1.40, a current ratio of 1.40 and a debt-to-equity ratio of 1.43. Lumexa Imaging has a fifty-two week low of $6.45 and a fifty-two week high of $19.45.

Analyst Ratings Changes

Several research analysts have recently issued reports on LMRI shares. Deutsche Bank Aktiengesellschaft set a $16.00 price objective on shares of Lumexa Imaging in a report on Thursday. Wall Street Zen downgraded Lumexa Imaging from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings raised Lumexa Imaging from a “sell (e)” rating to a “sell (d)” rating in a research note on Thursday, June 25th. Finally, Barclays lowered their target price on Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating on the stock in a report on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.00.

Insider Transactions at Lumexa Imaging

In related news, Director Brett Brodnax purchased 35,000 shares of the company’s stock in a transaction on Tuesday, May 19th. The shares were bought at an average price of $7.25 per share, with a total value of $253,750.00. Following the completion of the acquisition, the director owned 62,027 shares of the company’s stock, valued at approximately $449,695.75. This represents a 129.50% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Lumexa Imaging

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC purchased a new position in Lumexa Imaging in the 4th quarter worth about $1,548,000. Goldman Sachs Group Inc. acquired a new position in shares of Lumexa Imaging in the fourth quarter worth about $18,870,000. TD Asset Management Inc purchased a new position in shares of Lumexa Imaging in the fourth quarter worth approximately $1,264,000. JPMorgan Chase & Co. purchased a new position in shares of Lumexa Imaging in the fourth quarter worth approximately $15,954,000. Finally, Federated Hermes Inc. acquired a new stake in shares of Lumexa Imaging during the fourth quarter valued at approximately $8,325,000.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).